Approval · Notice of Compliance 35483 · 2025
VANFLYTA: Notice of Compliance 35483
Issued June 9, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35483
- Date
- June 9, 2025
- Company
- Daiichi Sankyo Pharma Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
Medicinal ingredients
- QUIZARTINIB HYDROCHLORIDE 17.7 MG per TAB
- QUIZARTINIB HYDROCHLORIDE 26.5 MG per TAB